
June 11 (Reuters) - Bristol-Myers Squibb Co BMY.N:
BRISTOL MYERS SQUIBB PRESENTS LATE-BREAKING DATA FROM PIVOTAL PHASE 3 POETYK PSA-1 TRIAL DEMONSTRATING SUPERIORITY OF SOTYKTU (DEUCRAVACITINIB) COMPARED WITH PLACEBO IN ADULTS WITH PSORIATIC ARTHRITIS
BRISTOL-MYERS SQUIBB CO - SOTYKTU DEMONSTRATES CONSISTENT SAFETY PROFILE WITH NO NEW SAFETY SIGNALS
BRISTOL-MYERS SQUIBB CO - SOTYKTU ACHIEVES PRIMARY ENDPOINT WITH 54.2% ACR20 RESPONSE AT WEEK 16